The bacterial agent Bacillus thuringiensis israelensis (Bti) is a highly effective larvicide against various medically important mosquito and black fly vector species. Recent formulations of this powerful larvicidal tool have been evaluated for their field efficacy in integrated mosquito management programs. Laboratory and controlled-condition trials have indicated long periods of residual efficacy, whereas field persistence is often much lower in duration. We investigated the residual persistence of high doses of 2 formulations of Bti, a water-dispersible granule (VectoBac® WDG; 16 mg/liter) and an extruded pellet (VBC-60066; 80 mg/liter), for the management of natural larval populations of Aedes albopictus. Laboratory tests demonstrated 100% (WDG) and ≥99.7% (VBC) average mortality across all treatments over 180 days. Field tests exhibited 100% efficacy (WDG and VBC) for 3 wk against Ae. albopictus and other coinhabiting mosquito species, with some residual efficacy lasting for >4 wk. These results are discussed in relation to current field control of domestic Aedes vectors of public health significance.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.